Eterna Therapeutics
ERNA
11 hedge funds and large institutions have $627K invested in Eterna Therapeutics in 2025 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 3 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
11% more capital invested
Capital invested by funds: $566K → $627K (+$61.1K)
0% more funds holding
Funds holding: 11 → 11 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0.08% less ownership
Funds ownership: 6.74% → 6.66% (-0.08%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$33.7K |
| 2 |
HF
HRT Financial
New York
|
+$17.2K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$4.33K |
| 4 |
FFO
Fortitude Family Office
Scottsdale,
Arizona
|
+$1.09K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$817 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$33.8K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$5.67K |
| 3 |
EWA
EverSource Wealth Advisors
Birmingham,
Alabama
|
-$127 |
| 4 |
Morgan Stanley
New York
|
-$68 |
ERNA Hedge Fund Activity: Q4 2025 in Review
11 of the 8,281 institutional investors tracked by Wall St. Rank reported a position in Eterna Therapeutics (ERNA) for Q4 2025, worth a combined $627K — up 11% from $566K a quarter earlier.
Fund positioning in ERNA was balanced in Q4 2025: 3 funds opened new positions, 3 closed out, 2 added to existing stakes and 1 trimmed.
The largest buyer was Vanguard Group, adding an estimated $33.7K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $33.8K sold.
- 11 institutional investors held Eterna Therapeutics (ERNA) as of Q4 2025, unchanged from Q3 2025.
- Funds reported $627K of Eterna Therapeutics stock for Q4 2025, up 11% quarter-over-quarter.
- 3 funds opened new Eterna Therapeutics positions in Q4 2025 and 3 closed out, a net change of 0 holders.
- The largest Eterna Therapeutics buyer in Q4 2025 was Vanguard Group, an estimated $33.7K added.
- The largest Eterna Therapeutics seller in Q4 2025 was Susquehanna International Group, an estimated $33.8K sold.
Based on aggregated 13F filings for Q4 2025.